SEARCH:   Advanced

Blood, 1 January 2005, Vol. 105, No. 1, pp. 358-360. Prepublished online as a Blood First Edition Paper on August 31, 2004; DOI 10.1182/blood-2004-04-1363. This Article Full Text (PDF) All Versions of this Article: 2004-04-1363v1 105/1/358    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chang, H. Articles by Stewart, A K Search for Related Content PubMed PubMed Citation Articles by Chang, H. Articles by Stewart, A K Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 9, 2004 Accepted August 16, 2004 P53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation Hong Chang*, Connie Qi, Qi-Long Yi, Donna Reece, and A K Stewart Department of Laboratory Hematology, Princess Margaret Hospital/University Health Network, Toronto, Canada; Department of Laboratory Medicine and Pathobiology, Princess Margaret Hospital/University Health Network, Toronto, Canada Department of Biostatistics, Princess Margaret Hospital/University Health Network, Toronto, Canada Department of Medical Oncology and Hematology, Princess Margaret Hospital/University Health Network, Toronto, Canada Department of Medical Oncology and Hematology, Princess Margaret Hospital/University Health Network, Toronto, Canada; McLaughlin Center for Molecular Medicine, University of Toronto, Toronto, Canada * Corresponding author; email: hong.chang{at}uhn.on.ca. We investigated the relevance of p53 deletions to the clinical outcome of multiple myeloma (MM) patients treated with high-dose chemotherapy and autologous stem cell transplantation. Hemizygous p53 gene deletions were detected by fluorescence in situ hybridization (FISH) in 10 of 105 (9.5%) patients studied. p53 deletions were associated with higher serum calcium (p=0.0062) and creatinine (p=0.013) levels but there were no association with patient age, gender, -2 microglobulin, C-reactive protein, hemoglobin, albumin or bone lytic lesions, or immunoglobulin isotype. There were no association of p53 deletions with 13q deletions, translocation t(11;14) or t(4;14). Patients with p53 deletions had significantly shorter progression free (median 7.9 vs. 25.7 months, p=0.0324) and overall survival (median 14.7 vs. 48.1 months, p=0.0008) than patients without a p53 deletion. A multivariate analysis confirmed p53 deletion was an independent prognostic factor predicting shortened progression free (p=0.0009) or overall survival (p=0.0002) in myeloma patients after high-dose chemotherapy and autologous stem cell transplantation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J.-L. Harousseau, M. Attal, and H. Avet-Loiseau The role of complete response in multiple myeloma Blood, October 8, 2009; 114(15): 3139 - 3146. [Abstract] [Full Text] [PDF] H. Avet-Loiseau, C. Li, F. Magrangeas, W. Gouraud, C. Charbonnel, J.-L. Harousseau, M. Attal, G. Marit, C. Mathiot, T. Facon, et al. Prognostic Significance of Copy-Number Alterations in Multiple Myeloma J. Clin. Oncol., September 20, 2009; 27(27): 4585 - 4590. [Abstract] [Full Text] [PDF] A. Kumar, M. A. Kharfan-Dabaja, A. Glasmacher, and B. Djulbegovic Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis J Natl Cancer Inst, January 21, 2009; 101(2): 100 - 106. [Abstract] [Full Text] [PDF] W. Xiong, X. Wu, S. Starnes, S. K. Johnson, J. Haessler, S. Wang, L. Chen, B. Barlogie, J. D. Shaughnessy Jr, and F. Zhan An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma Blood, November 15, 2008; 112(10): 4235 - 4246. [Abstract] [Full Text] [PDF] J Yeung and H Chang Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma J. Clin. Pathol., July 1, 2008; 61(7): 832 - 836. [Abstract] [Full Text] [PDF] N. C. Munshi Investigative Tools for Diagnosis and Management Hematology, January 1, 2008; 2008(1): 298 - 305. [Abstract] [Full Text] [PDF] A. K. Stewart A Risk-adapted Approach to Myeloma Therapy ASCO Educational Book, January 1, 2008; 2008(1): 380 - 384. [Abstract] [Full Text] [PDF] H. Avet-Loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, S. Leyvraz, M. Michallet, I. Yakoub-Agha, L. Garderet, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Blood, April 15, 2007; 109(8): 3489 - 3495. [Abstract] [Full Text] [PDF] A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al. Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement Mayo Clin. Proc., March 1, 2007; 82(3): 323 - 341. [Abstract] [Full Text] [PDF] T. Stuhmer, M. Chatterjee, M. Hildebrandt, P. Herrmann, H. Gollasch, C. Gerecke, S. Theurich, L. Cigliano, R. A. Manz, P. T. Daniel, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma Blood, November 15, 2005; 106(10): 3609 - 3617. [Abstract] [Full Text] [PDF] A. K. Stewart and R. Fonseca Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling J. Clin. Oncol., September 10, 2005; 23(26): 6339 - 6344. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020